Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer

doi:10.16352/j.issn.1001-6325.2023.03.514

Abstract

Abstract: Lung cancer is a leading cause of cancer-related morbidity and mortality in China. Early recurrence is the main cause of poor prognosis. The existing prognostic indicators are insufficient. Thus, it is urgent to find reliable prognostic indicators. DNA methylation is the most important epigenetic change in the development of lung cancer. With the development of high-throughput sequencing technology, DNA methylation has shown its great clinical value in the prognosis prediction of lung cancer patients due to its stable and detectable features.

Key words: lung cancer, DNA methylation, prognosis, epigenetics

CLC Number:

R734.2

XUE Jianchao, WANG Yadong, LI Bowen, LIU Xinyu, LIANG Naixin, LI Shanqing. Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer[J]. Basic & Clinical Medicine, 2023, 43(3): 514-518.

References

[1]Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209-249.
[2]Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2: 1-9.
[3]Bird A. DNA methylation patterns and epigenetic memory[J]. Genes Dev, 2002, 16: 6-21.
[4]Brzeziańska E, Dutkowska A, Antczak A. The significance of epigenetic alterations in lung carcinogenesis[J]. Mol Biol Rep, 2013, 40: 309-325.
[5]Shi YX, Sheng DQ, Cheng L, et al. Current landscape of epigenetics in lung cancer: focus on the mechanism and application[J]. J Oncol, 2019. doi: 10.1155/2019/8107318.
[6]Hoang PH, Landi MT. DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors[J]. Cancers (Basel), 2022, 14:961. doi: 10.3390/cancers14040961.
[7]Ehrlich M. DNA methylation in cancer: too much, but also too little[J]. Oncogene, 2002, 21: 5400-5413.
[8]Soozangar N, Sadeghi MR, Jeddi F, et al. Comparison of genome-wide analysis techniques to DNA methylation analysis in human cancer[J]. J Cell Physiol, 2018, 233: 3968-3981.
[9]Duruisseaux M, Esteller M. Lung cancer epigenetics: from knowledge to applications[J]. Semin Cancer Biol, 2018, 51: 116-128.
[10]Peng X, Liu X, Xu L, et al. The mSHOX2 is capable of assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer[J]. J Thorac Dis, 2019, 11: 2458-2469.
[11]Seok Y, Lee WK, Park JY, et al. TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients[J]. Mol Cells, 2019, 42: 161-165.
[12]Villalba M, Exposito F, Pajares MJ, et al. TMPRSS4: a novel tumor prognostic indicator for the stratification of stage IA tumors and a liquid biopsy biomarker for NSCLC patients[J]. J Clin Med, 2019, 8:2134. doi: 10.3390/jcm8122134.
[13]Dong Y, Huaying S, Danying W, et al. Significance of methylation of FBP1 gene in non-small cell lung cancer[J]. Biomed Res Int, 2018. doi: 10.1155/2018/3726091.
[14]Liu WB, Han F, Huang YS, et al. TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer[J]. Mol Carcinog, 2019, 58: 474-487.
[15]Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treat-ment in non-small-cell lung cancer: a multicentre, retrospective analysis[J]. Lancet Respir Med, 2018, 6: 771-781.
[16]Han Y, Shi K, Zhou SJ, et al. The clinicopathological significance of hMLH1 hypermethylation in non-small-cell lung cancer: a meta-analysis and literature review[J]. Onco Targets Ther, 2016, 9: 5081-5090.
[17]Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer[J]. J Clin Oncol, 2013, 31: 4140-4147.
[18]Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer[J]. N Engl J Med, 2008, 358: 1118-1128.
[19]Zhu Q, Wang J, Zhang Q, et al. Methylation driven genes PMPCAP1, SOWAHC and ZNF454 as potential prognostic biomarkers in lung squamous cell carcinoma[J]. Mol Med Rep, 2020, 21: 1285-1295.
[20]Gao C, Zhuang J, Li H, et al. Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma[J]. Cancer Cell Int, 2018, 18: 194. doi: 10.1186/s12935-018-0691-z.
[21]Kou W, Li B, Shi Y, et al. High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis[J]. BMC Cancer, 2022, 22: 110. doi: 10.1186/s12885-021-08912-3.
[22]Wang Y, Deng H, Xin S, et al. Prognostic and predictive value of three DNA methylation signatures in lung adenocarcinoma[J]. Front Genet, 2019, 10: 349. doi: 10.3389/fgene.2019.00349.
[23]Luo R, Song J, Xiao X, et al. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma[J]. Aging (Albany N Y), 2020, 12: 14649-14676.
[24]Koch A, Joosten SC, Feng Z, et al. Analysis of DNA methylation in cancer: location revisited[J]. Nat Rev Clin Oncol, 2018, 15: 459-466.